Shuttle Pharmaceuticals Holdings Management
Management criteria checks 4/4
Shuttle Pharmaceuticals Holdings' CEO is Anatoly Dritschilo, appointed in Dec 2012, has a tenure of 12.17 years. total yearly compensation is $274.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 14.63% of the company’s shares, worth $403.76K. The average tenure of the management team and the board of directors is 12.2 years and 8.1 years respectively.
Key information
Anatoly Dritschilo
Chief executive officer
US$274.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 12.2yrs |
| CEO ownership | 14.6% |
| Management average tenure | 12.2yrs |
| Board average tenure | 8.1yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$7m |
| Dec 31 2023 | US$399k | US$287k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$5m |
| Mar 31 2023 | n/a | n/a | -US$3m |
| Dec 31 2022 | US$269k | US$97k | -US$3m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | US$190k | US$19k | -US$1m |
| Dec 31 2020 | US$35k | US$35k | -US$909k |
Compensation vs Market: Anatoly's total compensation ($USD274.00K) is below average for companies of similar size in the US market ($USD640.92K).
Compensation vs Earnings: Anatoly's compensation has been consistent with company performance over the past year.
CEO
Anatoly Dritschilo (80 yo)
12.2yrs
Tenure
US$274,000
Compensation
Dr. Anatoly Dritschilo, M.D. serves as Member of Advisory Board of RetinalGeniX Technologies Inc since December 2023. He co-founded Shuttle Pharmaceuticals Holdings, Inc. since its formation in December 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.2yrs | US$274.00k | 14.63% $ 403.8k | |
| President & COO | 12.2yrs | US$236.00k | 0.022% $ 617.3 | |
| Co-Founder & Chief Scientific Officer for Biology | 12.2yrs | no data | 3.7% $ 102.2k | |
| Chief Financial Officer | less than a year | US$277.51k | 0% $ 0 | |
| Chief Clinical Officer & Chief Medical Officer | no data | US$218.00k | 0.0083% $ 228.8 | |
| Co-Founder & Director | 12.2yrs | no data | 3.76% $ 103.8k | |
| General Counsel | no data | no data | no data |
12.2yrs
Average Tenure
70yo
Average Age
Experienced Management: SHPH's management team is seasoned and experienced (12.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.2yrs | US$274.00k | 14.63% $ 403.8k | |
| Co-Founder & Director | 12.2yrs | no data | 3.76% $ 103.8k | |
| Chairman of Scientific Advisory Committee | 7.1yrs | US$93.70k | no data | |
| Member of Scientific Advisory Committee | 12.1yrs | no data | no data | |
| Independent Director | 12.2yrs | no data | 0.0058% $ 161.2 | |
| Member of Scientific Advisory Committee | 8.1yrs | no data | no data | |
| Independent Director | 5.8yrs | no data | 0.0058% $ 161.2 | |
| Independent Director | 4.1yrs | no data | 0.0095% $ 262.7 | |
| Member of Scientific Advisory Committee | 4.1yrs | no data | no data | |
| Member of Scientific Advisory Committee | 8.1yrs | no data | no data | |
| Independent Director | 2.3yrs | no data | 0.052% $ 1.4k |
8.1yrs
Average Tenure
65yo
Average Age
Experienced Board: SHPH's board of directors are considered experienced (8.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 02:34 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shuttle Pharmaceuticals Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|